• What are the treatment drivers and goals for [[indication]]?
  • What drug attributes are key influences, which have limited impact, and which are hidden opportunities?
  • How do current therapies perform on key treatment drivers and goals for [[indication]]?
  • What are the prevailing areas of unmet need and opportunity in [[indication]]?
  • What trade-offs across different clinical attributes and price are acceptable to U.S. and European [[physician type, plural]] for a hypothetical new [[indication]] drug?


Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of [[XX]] U.S. and [[XX]] European [[physician type, plural]] fielded in [[Month. Year]]

Key companies: [[key company 1]], [[key company 2]], [[key company 3]]

Key drugs: [[key drug 1]], [[key drug 2]], [[key drug 3]]

Table of contents

  • Detailed, Expanded Analysis (US/FR/DEU/UK)
    • Coming Soon
      • Coming Soon

Author(s): Bethany A. Kiernan, PhD

Bethany A. Kiernan, is a senior director in the central nervous system/ophthalmology disorders unit of Decision Resources Group. While at Decision Resources Group, Dr. Kiernan has covered the market dynamics of numerous indications, including schizophrenia, depression, migraine, multiple sclerosis, epilepsy, and other disorders. Dr. Kiernan’s previous experience includes eight years of scientific research conducted at Tufts University School of Medicine, Case Western Reserve University, and the College of the Holy Cross. Dr. Kiernan earned her degree from Case Western Reserve University.